Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
Identifieur interne : 001B33 ( Ncbi/Curation ); précédent : 001B32; suivant : 001B34Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
Auteurs : Regina Katzenschlager [Royaume-Uni] ; Michael J. Jackson ; Sarah Rose ; Kim Stockwell ; Kayhan A. Tayarani-Binazir ; Mohammed Zubair ; Lance A. Smith ; Peter Jenner ; Andrew J. LeesSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2007.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Administration, Oral, Animals, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (toxicity), Benserazide (administration & dosage), Benserazide (toxicity), Callithrix, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Infusions, Intravenous, Levodopa (administration & dosage), Levodopa (toxicity), Locomotion (drug effects), MSH Release-Inhibiting Hormone (administration & dosage), MSH Release-Inhibiting Hormone (toxicity), Male, Motor Activity (drug effects), Parkinsonian Disorders (drug therapy).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Benserazide, Levodopa, MSH Release-Inhibiting Hormone.
- chemical , toxicity : Antiparkinson Agents, Benserazide, Levodopa, MSH Release-Inhibiting Hormone.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- drug effects : Locomotion, Motor Activity.
- drug therapy : Parkinsonian Disorders.
- Administration, Oral, Animals, Callithrix, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Infusions, Intravenous, Male.
Abstract
The neuropeptide melanocyte-inhibiting factor (MIF) or L-propyl-L-leucyl-glycinamide (PLG) has been reported in some studies to improve the motor signs of Parkinson's disease (PD) and in rodent models of PD. In this study of oral and intravenous MIF in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmosets, a wide range of doses of MIF administered alone (0.25, 1, 2, 5, 10, 20 mg/kg orally) did not increase locomotor activity, relieve motor disability, or induce dyskinesias. When MIF (1.0 and 5.0 mg/kg orally or 10 and 20 mg/kg intravenously) was administered concomitantly with levodopa/benserazide, no significant differences in motor function or dyskinesias were observed compared with levodopa/benserazide alone. The results of this first study of MIF in the marmoset MPTP model provide no encouragement for the reinvestigation of MIF in the clinical management of the motor signs of PD.
DOI: 10.1002/mds.21256
PubMed: 17373723
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002806
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002806
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002975
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001B33
Links to Exploration step
pubmed:17373723Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.</title><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name><affiliation wicri:level="1"><nlm:affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London</wicri:regionArea><wicri:noRegion>University College London</wicri:noRegion></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J" last="Jackson">Michael J. Jackson</name></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name></author><author><name sortKey="Stockwell, Kim" sort="Stockwell, Kim" uniqKey="Stockwell K" first="Kim" last="Stockwell">Kim Stockwell</name></author><author><name sortKey="Tayarani Binazir, Kayhan A" sort="Tayarani Binazir, Kayhan A" uniqKey="Tayarani Binazir K" first="Kayhan A" last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name></author><author><name sortKey="Zubair, Mohammed" sort="Zubair, Mohammed" uniqKey="Zubair M" first="Mohammed" last="Zubair">Mohammed Zubair</name></author><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A" last="Smith">Lance A. Smith</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J" last="Lees">Andrew J. Lees</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1002/mds.21256</idno><idno type="RBID">pubmed:17373723</idno><idno type="pmid">17373723</idno><idno type="wicri:Area/PubMed/Corpus">002806</idno><idno type="wicri:Area/PubMed/Curation">002806</idno><idno type="wicri:Area/PubMed/Checkpoint">002975</idno><idno type="wicri:Area/Ncbi/Merge">001B33</idno><idno type="wicri:Area/Ncbi/Curation">001B33</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.</title><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name><affiliation wicri:level="1"><nlm:affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London</wicri:regionArea><wicri:noRegion>University College London</wicri:noRegion></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J" last="Jackson">Michael J. Jackson</name></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name></author><author><name sortKey="Stockwell, Kim" sort="Stockwell, Kim" uniqKey="Stockwell K" first="Kim" last="Stockwell">Kim Stockwell</name></author><author><name sortKey="Tayarani Binazir, Kayhan A" sort="Tayarani Binazir, Kayhan A" uniqKey="Tayarani Binazir K" first="Kayhan A" last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name></author><author><name sortKey="Zubair, Mohammed" sort="Zubair, Mohammed" uniqKey="Zubair M" first="Mohammed" last="Zubair">Mohammed Zubair</name></author><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A" last="Smith">Lance A. Smith</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J" last="Lees">Andrew J. Lees</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Administration, Oral</term><term>Animals</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (toxicity)</term><term>Benserazide (administration & dosage)</term><term>Benserazide (toxicity)</term><term>Callithrix</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Female</term><term>Infusions, Intravenous</term><term>Levodopa (administration & dosage)</term><term>Levodopa (toxicity)</term><term>Locomotion (drug effects)</term><term>MSH Release-Inhibiting Hormone (administration & dosage)</term><term>MSH Release-Inhibiting Hormone (toxicity)</term><term>Male</term><term>Motor Activity (drug effects)</term><term>Parkinsonian Disorders (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Benserazide</term><term>Levodopa</term><term>MSH Release-Inhibiting Hormone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Antiparkinson Agents</term><term>Benserazide</term><term>Levodopa</term><term>MSH Release-Inhibiting Hormone</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Locomotion</term><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Callithrix</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Female</term><term>Infusions, Intravenous</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The neuropeptide melanocyte-inhibiting factor (MIF) or L-propyl-L-leucyl-glycinamide (PLG) has been reported in some studies to improve the motor signs of Parkinson's disease (PD) and in rodent models of PD. In this study of oral and intravenous MIF in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmosets, a wide range of doses of MIF administered alone (0.25, 1, 2, 5, 10, 20 mg/kg orally) did not increase locomotor activity, relieve motor disability, or induce dyskinesias. When MIF (1.0 and 5.0 mg/kg orally or 10 and 20 mg/kg intravenously) was administered concomitantly with levodopa/benserazide, no significant differences in motor function or dyskinesias were observed compared with levodopa/benserazide alone. The results of this first study of MIF in the marmoset MPTP model provide no encouragement for the reinvestigation of MIF in the clinical management of the motor signs of PD.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001B33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:17373723
|texte= Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:17373723" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |